FINANCIAL HIGHLIGHTS Six months ended 30 June 2025 2026 RMB’000 RMB’000 Decrease % Revenue 6,165,949 7,518,683 (18.0%) EBITDA 920,817 2,752,120 (66.5%) Profit before taxation 465,143 2,419,651 (80.8%) Profit for the period attributable to the…
FINANCIAL HIGHLIGHTS
Six months ended 30 June
2025
2026
RMB’000
RMB’000
Decrease
%
Revenue
6,165,949
7,518,683
(18.0%)
EBITDA
920,817
2,752,120
(66.5%)
Profit before taxation
465,143
2,419,651
(80.8%)
Profit for the period attributable to
the owners of the Company
347,644
1,894,314
(81.6%)
RMB cents
17.62
RMB cents
104.26
(83.1%)
16.0
(100.0%)
Earnings per share - Basic
Interim dividend (per share)
-1-
The Board of Directors (the “Board”) of The United Laboratories International Holdings Limited (the
“Company”) announces the unaudited condensed consolidated results of the Company and its subsidiaries
(the “Group”) for the six months ended 30 June 2026 together with the comparative figures for the
corresponding period in 2025 as follows:
CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
AND OTHER COMPREHENSIVE INCOME
FOR THE SIX MONTHS ENDED 30 JUNE 2026
Notes
Revenue
Cost of sales
3
Six months ended 30 June
2025
2026
RMB’000
RMB’000
(Unaudited)
(Unaudited)
6,165,949
(4,046,465)
7,518,683
(3,594,809)
2,119,484
138,498
(177,874)
(678,006)
(458,059)
(438,925)
(9,423)
3,923,874
128,480
61,183
(682,161)
(435,200)
(498,941)
(40,531)
6
14,132
264
(44,948)
(16,284)
28
(20,797)
Profit before taxation
Tax expense
7
465,143
(120,978)
2,419,651
(526,144)
Profit for the period
8
344,165
1,893,507
Other comprehensive income (expense)
Item that may be reclassified subsequently to
profit or loss:
Exchange differences arising on translation
of foreign operations
4,193
(684)
Total comprehensive income for the period
348,358
1,892,823
Profit (loss) for the period attributable to:
Owners of the Company
Non-controlling interests
347,644
(3,479)
1,894,314
(807)
344,165
1,893,507
351,837
(3,479)
1,893,630
(807)
348,358
1,892,823
RMB cents
17.62
RMB cents
104.26
Gross profit
Other income
Other gains and losses, net
Selling and distribution expenses
Administrative expenses
Research and development expenditures
Other expenses
Impairment losses reversed (recognised) under
expected credit loss model, net of reversal
Share of results of an associate
Finance costs
4
5
Total comprehensive income (expense) for the period
attributable to:
Owners of the Company
Non-controlling interests
Earnings per share
9
-2-
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AT 30 JUNE 2026
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
11,582,023
449,273
3,031
293,247
7,325
104,770
1,402
84,341
12,525,412
11,557,901
441,833
3,031
274,195
7,061
75,818
3,729
67,399
12,430,967
2,680,279
2,369,133
12
15
5,159,174
660,248
1,728
16,474
11,069,413
19,587,316
4,741,718
628,503
123,765
10,606,390
18,469,509
13
7,830,128
32,306
512,987
14,136
4,040
1,180,823
9,574,420
7,890,941
76,785
4,969
2,106,458
10,079,153
Net current assets
10,012,896
8,390,356
Total assets less current liabilities
22,538,308
20,821,323
Notes
Non-current assets
Property, plant and equipment
Right-of-use assets
Goodwill
Intangible assets
Interests in an associate
Deposits for acquisition of property, plant and equipment
Deposits for acquisition of intangible assets
Deferred tax assets
Current assets
Inventories
Trade and bills receivables, other receivables,
deposits and prepayments
Pledged bank deposits
Derivative financial instruments
Tax recoverable
Cash and cash equivalents
Current liabilities
Trade and other payables
Contract liabilities
Dividend payables
Derivative financial instruments
Lease liabilities
Borrowings - due within one year
11
10
-3-
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION - continued
AT 30 JUNE 2026
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
361,934
95,506
22,066
19,852
4,743,600
376,079
89,644
7,453
2,872,831
5,242,958
3,346,007
Net assets
17,295,350
17,475,316
Capital and reserves
Share capital
Reserves
18,396
17,198,071
18,396
17,374,558
17,216,467
78,883
17,392,954
82,362
17,295,350
17,475,316
Note
Non-current liabilities
Deferred tax liabilities
Deferred income in respect of government grants
Derivative financial instruments
Lease liabilities
Borrowings - due after one year
13
Equity attributable to owners of the Company
Non-controlling interests
Total equity
-4-
NOTES TO FINANCIAL STATEMENTS
1.
BASIS OF PREPARATION
The condensed consolidated financial statements have been prepared in accordance with Hong Kong
Accounting Standard 34 “Interim Financial Reporting” issued by the Hong Kong Institute of Certified
Public Accountants (the “HKICPA”) as well as the applicable disclosure requirements of the Rules
Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“Stock
Exchange”)(the “Listing Rules”).
PRINCIPAL ACCOUNTING POLICIES
The condensed consolidated financial statements have been prepared on the historical cost basis except
for certain financial instruments, which are measured at fair values.
Other than change in accounting policies resulting from the application of amendments to HKFRS
Accounting Standards, the accounting policies and methods of computation used in the condensed
consolidated financial statements for the six months ended 30 June 2026 are the same as those
presented in the Group’s annual consolidated financial statements for the year ended 31 December
2025.
Application of amendments to HKFRS Accounting Standards
In the current interim period, the Group has applied the following amendments to HKFRS Accounting
Standards issued by the HKICPA, for the first time, which are mandatorily effective for the Group’s
annual period beginning on 1 January 2026 for the preparation of the Group’s condensed consolidated
financial statements:
Amendments to HKFRS 9
and HKFRS 7
Amendments to HKFRS 9
and HKFRS 7
Amendments to HKFRS
Accounting Standards
Amendments to the Classification and Measurement of
Financial Instruments
Contracts Referencing Nature-dependent Electricity
Annual Improvements to HKFRS Accounting
Standards - Volume 11
The application of the amendments to HKFRS Accounting Standards in the current interim period has
had no material impact on the Group’s financial positions and performance for the current and prior
periods and/or on the disclosures set out in these condensed consolidated financial statements.
3.
REVENUE AND SEGMENT INFORMATION
The Group is currently organised into three revenue streams, including Intermediate products, Bulk
medicine and Finished products.
Specifically, the Group’s reportable segments under HKFRS 8 are as follows:
1)
2)
3)
Intermediate products - mainly represent sales of 6-APA products and penicillin G potassium
products;
Bulk medicine - mainly represent sales of amoxicillin products; and
Finished products - mainly represent sales of insulin series products, antibiotics products,
ophthalmic products, veterinary drugs and license fee income.
The three revenue streams are the operating and reportable segments of the Group on which the Group
reports its primary segment information.
-5-
REVENUE AND SEGMENT INFORMATION - Continued
(a) Segment Revenue and Results
For the six months ended 30 June 2026 (Unaudited)
Intermediate
Bulk
Finished
Segments
products
medicine
products
total
Elimination
Consolidated
RMB’000
RMB’000
RMB’000
RMB’000
RMB’000
RMB’000
703,883
2,595,505
2,764,696
6,064,084
Inter-segment sales
1,272,571
552,898
1,825,469
(1,825,469)
License fee income
101,865
101,865
101,865
1,976,454
3,148,403
2,866,561
7,991,418
(1,825,469)
6,165,949
Segment profit before research and
development expenses
290,060
127,930
690,022
1,108,012
Research and development expenses
(included in the measurement
of segment profit)
(98,646)
(48,278)
(292,001)
(438,925)
191,414
79,652
398,021
669,087
REVENUE
External sales
Segment revenue
6,064,084
RESULT
Segment profit
Share of results of an associate
264
Unallocated other income
87,627
Unallocated corporate expenses
Unallocated other gains and
losses, net
Impairment losses of other
receivables under expected
credit loss model, net of reversal
(69,400)
(178,305)
818
Finance costs
(44,948)
Profit before taxation
465,143
-6-
REVENUE AND SEGMENT INFORMATION - Continued
(a) Segment Revenue and Results - continued
For the six months ended 30 June 2025 (Unaudited)
Intermediate
Bulk
Finished
Segments
products
medicine
products
total
Elimination
Consolidated
RMB’000
RMB’000
RMB’000
RMB’000
RMB’000
RMB’000
External sales
1,010,665
2,529,547
2,544,571
6,084,783
Inter-segment sales
1,293,646
469,767
1,763,413
(1,763,413)
License fee income
1,433,900
1,433,900
1,433,900
2,304,311
2,999,314
3,978,471
9,282,096
(1,763,413)
7,518,683
Segment profit before research and
development expenses
798,889
275,776
1,815,116
2,889,781
Research and development expenses
(included in the measurement
of segment profit)
(164,270)
(25,127)
(309,544)
(498,941)
634,619
250,649
1,505,572
2,390,840
REVENUE
Segment revenue
6,084,783
RESULT
Segment profit
Share of results of an associate
28
Unallocated other income
76,026
Unallocated corporate expenses
Unallocated other gains and
losses, net
Impairment losses of other
receivables under expected
credit loss model, net of reversal
(123,733)
Finance costs
(20,797)
95,036
2,251
Profit before taxation
2,419,651
(b) Geographical Information
The revenue from the external customers by geographical market (irrespective of the origin of the
goods) based on the location of the customers are presented below:
Six months ended 30 June
2025
2026
RMB’000
RMB’000
(Unaudited)
(Unaudited)
The People’s Republic of China (“PRC”),
including Hong Kong (country of domicile)
Europe
India
Middle East
South America
Other Asian regions
Other regions
-7-
4,830,311
402,011
182,254
12,809
373,154
266,483
98,927
4,725,243
1,741,465
197,687
13,641
450,590
258,367
131,690
6,165,949
7,518,683
OTHER INCOME
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Bank interest income
Sales of scrap materials
Subsidy income (Note)
Sundry income
85,397
3,020
42,483
7,598
65,468
3,133
54,959
4,920
138,498
128,480
Note: Subsidy income includes tax subsidy and government grants from the PRC government which
are specifically for (i) the capital expenditure incurred for plant and machinery, which is
recognised as income over the useful life of the related assets; (ii) the incentives and other
subsidies for research and development activities, which are recognised upon meeting the
attached conditions; and (iii) the incentives which have no specific conditions attached to the
grants.
5.
OTHER GAINS AND LOSSES, NET
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Net foreign exchange loss
Net gain on fair value change of derivative financial
instruments
(Loss) gain on disposal of financial assets at fair value through
profit or loss
Net gain on disposal of property, plant and equipment
Loss on disposal of leasehold land
Written-off of property, plant and equipment
Others
(186,246)
(37,058)
17,398
72,973
(7,436)
344
(652)
(1,325)
43
74,971
7,556
(57,389)
130
(177,874)
61,183
FINANCE COSTS
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Interest on borrowings
Interest on lease liabilities
Less: amounts capitalised in property, plant and equipment
55,857
662
56,519
(11,571)
41,229
377
41,606
(20,809)
44,948
20,797
Borrowing costs capitalised during the current interim period arose on the general borrowing pool and
are calculated by applying a capitalisation rate of 2.56% (six months ended 30 June 2025: 2.55%) per
annum to expenditure on qualifying assets.
-8-
TAX EXPENSE
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Current tax
Hong Kong profits tax
PRC enterprise income tax (“EIT”)
PRC withholding tax on distributed profits of PRC subsidiaries
Danish withholding tax on licensing fee income
Deferred tax (credit) charge
334
105,860
35,684
10,187
152,065
(31,087)
923
306,813
143,390
451,126
75,018
Tax expense
120,978
526,144
Hong Kong Profits Tax is calculated at 16.5% of the estimated assessable profits for both periods.
PRC EIT is calculated at the applicable rates of tax prevailing in the areas in which the Group operates,
based on the existing legislation, interpretations and practices.
Pursuant to the Danish domestic tax law, the withholding tax on royalty payment in Denmark is subject
to withholding tax at the statutory rate of 22% on the gross amount. Under the applicable double tax
arrangement, the Group is entitled to a reduced rate of 10% for current period.
8.
PROFIT FOR THE PERIOD
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Profit for the period has been arrived at after charging/(crediting):
Staff costs, including directors’ emoluments
Salaries and other benefits
Contributions to retirement benefit schemes
Share-based compensation expense
971,995
189,676
4,429
1,166,100
931,912
169,008
11,725
1,112,645
Depreciation
Depreciation of right-of-use assets
Depreciation of property, plant and equipment
16,108
381,201
8,476
293,014
Amortisation of intangible assets (included in cost of sales)
13,417
10,182
Write-down of inventories (reversed) recognised, net (included in
cost of sales)
Cost of inventories recognised as expenses
(39,680)
2,824
4,006,785
3,526,447
-9-
EARNINGS PER SHARE
The calculation of basic earnings per share attributable to the owners of the Company is based on the
following data:
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Earnings
Earnings for the purposes of basic earnings per share being
profit for the period attributable to the owners of the Company
347,644
1,894,314
Six months ended 30 June
2026
2025
’000
’000
(Unaudited)
(Unaudited)
Number of shares
Weighted average number of ordinary shares
for the purpose of basic earnings per share
1,972,631
1,816,934
No diluted earnings per share for the six months ended 30 June 2026 and 2025 were presented as there
were no potential ordinary shares in issue for both periods.
10. DIVIDENDS
Six months ended 30 June
Dividends for ordinary shareholders of the Company
recognised as distribution during the period
- 2025 final dividend RMB26 cents
(2025: 2024 final dividend RMB28 cents) per share
- 2024 special dividend RMB12 cents per share
2026
RMB’000
(Unaudited)
2025
RMB’000
(Unaudited)
512,987
508,767
218,044
512,987
726,811
The 2025 final dividend has been subsequently settled in July 2026.
The Board does not recommend payment of an interim dividend for the six months ended 30 June 2026
(six months ended 30 June 2025: RMB16 cents per share).
11. MOVEMENTS IN PROPERTY, PLANT AND EQUIPMENT
The Group incurred approximately RMB429,637,000 (six months ended 30 June 2025:
RMB1,639,948,000) on addition of property, plant and equipment to expand and upgrade certain
production plants and office buildings primarily in the PRC, during the six months ended 30 June 2026.
During the current interim period, the Group disposed of and written off of certain plant and machinery
with an aggregate carrying amount of RMB20,014,000 (six months ended 30 June 2025:
RMB70,559,000) for cash proceeds of RMB19,033,000 (six months ended 30 June 2025:
RMB20,726,000), resulting in a gain on disposal of RMB344,000 (six months ended 30 June 2025: gain
on disposal: RM7,556,000) and written off of RMB1,325,000 (six months ended 30 June 2025:
RMB57,389,000).
- TRADE AND BILLS RECEIVABLES, OTHER RECEIVABLES, DEPOSITS AND PREPAYMENTS
Trade receivables from contracts with customers
Less: allowance for credit losses
Banker’s acceptance bills receivables
Less: allowance for credit losses
Consideration receivables
Less: allowance for credit losses
Value-added tax receivables
Other receivables, deposits and prepayments
Less: allowance for credit losses
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
2,168,462
(7,588)
2,348,266
(3,489)
339,574
(339,574)
345,869
327,600
(19,948)
2,248,570
(31,812)
1,982,202
(174)
339,574
(339,574)
268,396
287,707
(13,171)
5,159,174
4,741,718
The Group normally allows a credit period of ranging from 45 days to 180 days (31 December 2025:
from 45 days to 180 days) to its trade customers, and may be extended to selected customers depending
on their trade volume and settlement with the Group. The banker’s acceptance bills receivables have a
general maturity period of between 90 days and 1 year (31 December 2025: between 90 days and 1
year).
The following is an analysis of trade receivables by age, net of allowance for credit losses, presented
based on dates of transferring control of the goods, and an analysis of banker’s acceptance bills
receivables by age, net of allowance for credit losses, presented based on the bills issuance date, at the
end of the reporting period:
Trade receivables from contracts with
customers
0 to 30 days
31 to 60 days
61 to 90 days
91 to 120 days
121 to 180 days
Over 180 days
Banker’s acceptance bills receivables
0 to 30 days
31 to 60 days
61 to 90 days
91 to 120 days
121 to 180 days
Over 180 days
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
1,047,485
419,144
356,495
232,921
98,654
6,175
1,018,465
414,069
333,415
191,235
128,585
130,989
2,160,874
2,216,758
422,191
382,445
472,730
433,472
613,968
19,971
362,012
305,817
418,932
381,778
497,646
15,843
2,344,777
1,982,028
- TRADE AND OTHER PAYABLES
The Group normally receives credit terms of up to 120 days and 180 days for trade payables and trade
payables under supplier finance arrangement, respectively, from its suppliers. The following is an
analysis of the trade payables and trade payables under supplier finance arrangement by age, presented
based on the invoice date or bills issuance date at the end of the reporting period:
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
1,209,672
726,523
114,740
2,050,935
1,234,969
355,830
20,415
1,611,214
1,476,905
912,382
2,389,287
986,000
1,242,006
484
2,228,490
558,393
187,511
64,392
262,779
455,011
105,011
693,970
204,743
60,222
312,627
558,132
90,338
1,852,315
2,220,849
30 June
Trade payables
0 to 90 days
91 to 180 days
Over 180 days
Trade payables under supplier finance arrangement (note)
0 to 90 days
91 to 180 days
Over 180 days
Other payables and accruals
Other tax payable
Accrual of freight expense
Accrual of salary, staff welfare and unclaimed annual leave
Accrual of water, electricity fee and steam
Deferred income in respect of government grants
Payables in respect of the acquisition of property, plant
and equipment
7,925,634
7,980,585
Less: Amount due within one year shown
under current liabilities
(7,830,128)
(7,890,941)
Amount shown under non-current liabilities
95,506
89,644
Note: These relate to trade payables in which the Group has issued banker’s acceptance bills to the
relevant suppliers for future settlement of trade payables. The Group continues to recognise
these trade payables as the relevant banks are obliged to make payments only on due dates of
the bills, under the same conditions as agreed with the suppliers without further extension.
14. CAPITAL COMMITMENTS
As at 30 June 2026, the Group had commitments for capital expenditure of RMB1,306,103,000 (31
December 2025: RMB1,319,378,000) in respect of the acquisition of property, plant and equipment
contracted for but not provided in the condensed consolidated financial statements.
- PLEDGE OF OR RESTRICTIONS ON ASSETS
Pledge of assets
The Group had pledged the following assets to banks as securities against banking facilities granted to
the Group at the end of the reporting period:
Property, plant and equipment, at net book value
Right-of-use assets, at net book value
Banker’s acceptance bills receivables
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
2,265,551
168,188
94,975
1,582,221
160,113
145,190
Restrictions on assets
In addition, lease liabilities of RMB 23,892,000 (31 December 2025: RMB 12,422,000 ) are recognised
with related right-of-use assets of RMB 25,101,000 (31 December 2025: RMB 11,682,000) as at 30 June
2026. The lease agreements do not impose any covenants other than the security interests in the leased
assets that are held by the lessor and the relevant leased assets may not be used as security for borrowing
purposes.
16. RELATED PARTY TRANSACTIONS
(a) The Group’s key management personnel are all directors of the Company, including chief
executives, and the remuneration to the directors of the Company during the period is as follows:
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Fees
Salaries and other benefits
Contributions to retirement benefits schemes
334
9,925
23
357
9,723
25
10,282
10,105
(b) During the current interim period, the Group entered into the following transactions with a related
party:
Name of related party
寧波普邦生物科技有限公司
Nature of
transaction/balance
Sale of goods
Trade advance
Trade and bills
receivables
Other receivables
Relationship
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Associate
Associate
Associate
55,876
75,292
1,541
3,612
84
Associate
6
MANAGEMENT DISCUSSION AND ANALYSIS
In the first half of 2026, China’s national economy withstood pressure and maintained an overall steady
development momentum. The pharmaceutical industry has accelerated its pace of innovative transformation
and global expansion. Meanwhile, policies such as medical insurance cost control and centralised
procurement have entered a phase of normalised operation, and enterprises have established mature response
models in pricing systems and cost management. Recently, the “National Health 15th Five-Year Plan”
explicitly proposed, for the first time, full-chain support for the development of innovative drugs. With the
continued release of policy dividends, the industry has entered a critical period of transformation and
upgrading.
Against this backdrop, the Group continued to advance its innovative R&D and global expansion strategies.
At the same time, the Group further tapped the market potential of its traditional core business to drive
quality improvement and efficiency enhancement. All business segments developed in a coordinated manner,
further consolidating the Group’s industry-leading position.
Innovative Research and Development
The Group regards innovative R&D as the core engine driving enterprise development, continuously
increasing R&D investment and attracting scientific talents. Through diversified collaboration models such
as independent R&D and cooperative development, it expanded its innovative product pipeline, enhanced
new drug R&D and clinical capabilities, and accelerated the development and practical application of
innovative technologies and products.
During the Period, the Group invested a total of RMB469,100,000 in pharmaceutical research and
development, with a year-on-year decrease in R&D of 14.8%, including expensed R&D investment of
RMB438,900,000 and capitalisation of R&D investment of RMB30,200,000.
The Group has established a comprehensive research and development system composed of multiple
platforms, including biological research and development, chemical drug research and development,
biological fermentation and chemical, enzymatic synthesis research and development, animal healthcare
research and development and clinical research center. At present, the Group had 40 new drug products
under development, of which 23 products are Class 1 new drugs, focusing on the areas of endocrinology,
metabolism, autoimmunity, ophthalmology and anti-infection; There are a total of 67 new animal healthcare
products under development, fully covering economic and companion animals. Furthermore, APIs, the
quality and efficacy consistency evaluation of generic drugs, and the research and development of projects
related to medical aesthetics are progressing steadily.
Progress in Research and Development
During the Period, the Group made the following major progress in R&D:
In January, the investigational new drug (IND) application for TUL108 for Injection, a Class I new
drug, was approved by the U.S. Food and Drug Administration (FDA).
In February, the application for the clinical trial of UBT251 Injection, a Class I new drug, for the
indication of moderate to severe obstructive sleep apnea (OSA) with obesity-related comorbidity,
received implied approval from China’s National Medical Products Administration (the “NMPA”).
In February, the Phase II clinical study of UBT251 Injection, a Class I new drug, was completed in
Chinese patients with overweight/obesity, achieving its predefined goals.
In February, Roxithromycin Capsules (specification: 150mg) passed the quality and efficacy
consistency evaluation of generic drugs.
In March, the Phase II clinical study of UBT251 Injection, a Class I new drug, was completed in
Chinese patients with Type 2 diabetes, achieving its predefined goals.
In March, the NDA of Insulin Degludec Injection (specifications: 3ml: 300U (refilled pen-type); 3ml:
300U (disposable pen-type)) was approved by the NMPA.
In April, the clinical trial of Dupilumab Injection received implied approval from the NMPA.
In April, the IND application for the clinical trial of TUL321 Capsules, a Class 1 new drug, was
approved by the FDA.
In May, the clinical trial of UBT38006 Injection, a Class 1 new drug, received implied approval from
the NMPA.
In May, the IND application for the clinical trial of TUL108 for Injection, a Class 1 new drug, received
implied approval from the NMPA.
In June, the IND application for the clinical trial of TUL321 Capsules, a Class 1 new drug, received
implied approval from the NMPA.
During the Period, the results of the Phase II clinical study of UBT251 Injection were presented at the 86th
Scientific Sessions of the American Diabetes Association (ADA). With the outstanding research data, such
results were successfully selected as the Late-Breaking Abstracts at such session, and were officially selected
by ADA for inclusion in the Press Briefing and Poster presentation.
During the Period, the Group recorded licensing fee income of US$15,000,000 (approximately RMB
101,900,000), being a milestone payment from Novo Nordisk S/A for a global Phase II clinical trial of
UBT251 Injection of overweight or obesity indication, in relation to the previous licensing of the global
(excluding Mainland China, Hong Kong SAR, Macau SAR, and Taiwan) development, manufacturing, and
commercialisation of UBT251 (GLP-1R/GIPR/GCGR triple agonist). This milestone payment represents the
steady progress of UBT251’s global clinical development and further validates its clinical value and
commercial potential. The licensing fee was received in July 2026.
Under the license agreement with Novo Nordisk S/A and subject to the terms and conditions thereof, The
United Bio-Technology (Hengqin) Co., Ltd. (a wholly-owned subsidiary of the Group) is eligible to receive
potential milestone payments of up to US$1.8 billion subject to the achievement of certain development and
sales milestones, plus tiered royalties based on annual net sales in the territory.
Class I new drugs under development
Project
Category
Indication
Phase
UBT251 Injection
UBT251 Injection
UBT251 Injection
UBT251 Injection
UBT251 Injection
UBT37034 for Injection
Chemical drug
Chemical drug
Chemical drug
Chemical drug
Chemical drug
Chemical drug
Overweight/Obesity
Diabetes
MASH
Chronic kidney disease
OSA
Overweight/Obesity
UBT38006 Injection
UBT48128 Tablets
Biological drug
Chemical drug
Diabetes
Diabetes/Weight
management
UBT43026 Oral Preparation
Chemical drug
UBT42
Biological drug
UBT49003 for Injection
Biological drug
UBT506 for Injection
Biological drug
Hyperlipoproteinemia,
atherosclerosis, aortic
valve stenosis, etc.
Vitiligo, alopecia areata,
other autoimmune diseases
Acute Lung Injury/Acute
Respiratory Distress
Syndrome (ALI/ARDS),
etc.
Moderate to severe
Eczema, Asthma
Phase III clinical trial
Phase III clinical trial
Phase II clinical trial
Phase II clinical trial
Phase III clinical trial
IND approved (United
States)
Phase I clinical trial (PRC)
Phase I clinical trial
IND approved (United
States)
Pre-clinical trial (PRC)
Pre-clinical trial
Pre-clinical trial
Pre-clinical trial
Pre-clinical trial
TUL01101 Tablets
TUL01101 Tablets
Chemical drug
Chemical drug
Rheumatoid arthritis
Moderate to severe atopic
dermatitis
Atopic dermatitis
Paroxysmal nocturnal
hemoglobinuria
TUL01101 Ointment
TUL321 Capsules
Chemical drug
Chemical drug
TUL12101 Eye Drops
TUL108 for Injection
Chemical drug
Chemical drug
Xerophthalmia
Drug-resistant bacterial
infection
LB2332
LB2249
LB2237
LB2343
Chemical drug
Chemical drug
Chemical drug
Chemical drug
Fungal infection
Fat loss and muscle gain
Hyperlipidemia
Drug-resistant bacterial
infection
Phase II clinical trial
Phase III clinical trial
Phase III clinical trial
IND approved (United
States)
Phase I clinical trial (PRC)
Phase II clinical trial
IND approved (United
States)
Phase I clinical trial (PRC)
Pre-clinical trial
Pre-clinical trial
Pre-clinical trial
Pre-clinical trial
BUSINESS REVIEW
Intermediate Products and Bulk Medicine Business
During the Period, the prices of major upstream products gradually stabilised and recovered, but remained
lower than the same period last year. The intermediate products and bulk medicine segments recorded
external sales of RMB703,900,000 and RMB2,595,500,000, respectively, representing a year-on-year
decrease of 30.4% and increase of 2.6%, respectively. Overseas export recorded sales of RMB1,026,100,000,
representing a year-on-year decrease of 5.1%, and accounting for 16.6% of the Group’s total revenue.
Currently, the bulk medicine industry remains in a phase of structural recovery. Relying on mature
large-scale production capabilities, the Group has accelerated its innovative R&D, continuously optimised
and refined its product mix, and consistently reinforced its core advantages within the industrial chain. In
addition, the Group has continued to advance its international development strategy, expanded its global
business footprint, deepened cooperation and exchanges with domestic and overseas customers, and further
enhanced brand influence and market competitiveness, providing strong support for the steady development
of the intermediate products and bulk medicine segments.
Finished Products Business
During the Period, the external sales of finished products was RMB2,866,600,000 (including license fee
income of RMB101,900,000), representing a year-on-year decrease of 27.9% and accounting for 46.5% of
the Group’s total revenue.
During the Period, in the national follow-up centralised procurement for drugs with expiring agreements
(LC-YPJX-2026-1), the Group had a total of 13 products successfully selected, including Piperacillin
Sodium and Tazobactam Sodium for Injection, Cefuroxime for Injection, Meropenem for Injection and
multiple eye drops. This follow-up procurement covered more than 300 commonly used drugs spanning the
1st to 8th batches of national centralised procurement, across multiple therapeutic areas such as anti-infection,
anti-tumour, nervous system, respiratory system and digestive system. The selection results were
implemented in March 2026. The Group is expected to further increase its market share of the relevant
selected products and consolidate its market advantages.
In addition, following the implementation of the “Measures for the Administration of Medical
Representatives” during the year, multi-department coordination, stringent market access and full-chain
closed-loop supervision will accelerate the in-depth restructuring of the pharmaceutical industry towards a
“professional academic-driven” model. While accelerating innovative transformation, the Group
continuously strengthens its compliance system and academic capability building, and is committed to
upgrading its marketing team towards greater professionalism and academic focus.
Endocrine/Metabolism
The main products include 優思靈 ®USLIN® (Human Insulin Injection (N/R/30R/50R)), 聯邦優樂靈
®
USLEN®(Insulin Glargine Injection), 聯邦優倍靈®UBLIN®(Insulin Aspart/Insulin Aspart 30 Injection),
聯邦優得靈 ®(Insulin Degludec Injection), 聯邦優利泰 ®(Liraglutide Injection), and 聯邦 ® 滅特尼
®
(Glipizide Tablets), etc.
During the Period, the Group’s first GLP-1 product, 聯邦優利泰®(Liraglutide Injection), continued to
expand its market coverage. In addition, the Group’s ultra-long-acting basal insulin analogue, 聯邦優得靈®
(Insulin Degludec Injection), was approved for marketing, further enriching the product matrix in the
endocrine/metabolism field.
During the Period, endocrine and metabolism products recorded total sales of RMB938,500,000,
representing a year-on-year decrease of 2.9%.
Anti-infection
The main products include 聯邦他唑仙®(Piperacillin Sodium Tazobactam Sodium for Injection), 聯邦®阿
莫仙®(Amoxicillin Capsules/Granules), 強力阿莫仙®(Potassium Amoxicillin Clavulanate for Injection,
Potassium Amoxicillin Clavulanate Tablets/Dry Suspensions), and 聯邦倍能安 ®(Imipenem Cestastatin
Sodium for Injection), among others.
During the Period, the anti-infection products (for human use) recorded total sales of RMB875,700,000,
representing a year-on-year decrease of 2.0%.
Other Human-use Finished Products
The main products include ophthalmic drugs, topical dermatological drugs, etc.
During the Period, other human-used finished products recorded total sales of RMB109,700,000,
representing a year-on-year increase of 0.9%.
Big Health
The main products include the United Health & Beauty series of healthcare products, United Biophin series
of skincare products, etc.
The Big Health Division of the Group has deployed five major product lines: general dietary supplements,
healthcare food products, cross-border nutritional supplements, medical devices, and medical and aesthetic
skincare products, covering categories such as bone and joint nutrition, intestinal regulation, cardiovascular
health, vision protection and immunity enhancement. At present, we have built a matrix of e-commerce, live
broadcasting and new retail online sales platforms represented by Tmall, JD.com, TikTok and WeChat Mall,
and deepened our coverage of pharmacy chains and health vertical pipelines.
During the Period, the big health segment recorded sales of RMB17,700,000, representing a year-on-year
increase of 58.0%.
Animal Healthcare
The Group’s animal healthcare business focuses on the research and development, production, sales and
technical services of economic and companion animal drugs, with products covering a full range of livestock,
poultry, aquatic products and pets. During the Period, we obtained 3 new veterinary drug registration
certificates.
In the first half of the year, under the concentrated challenges of strengthened policy supervision and
pressure from the breeding cycle, the veterinary drug industry maintained an overall development
momentum of steady growth in total volume and accelerated structural optimisation. The Group continues to
advance the development strategy of “One Core Business, Four New Growth Drivers” development strategy
and, leveraging its industrial advantages, is building global capabilities spanning R&D, production and sales.
The Group is strengthening the foundation of the livestock and poultry business and accelerating the
development of four new businesses: pet products, aquatic products, raw materials, and overseas expansion,
actively seizing market opportunities and industry development windows. At present, the Group has a total of
88 overseas registrations that have been obtained or are currently in progress.
During the Period, the animal healthcare segment recorded sales of RMB823,100,000, representing a
year-on-year increase of 45.8%.
FINANCIAL REVIEW
Financial Results
For the six months ended 30 June 2026, the Group recorded revenue of RMB6,165.9 million, a decrease of
18.0% as compared with the same period last year. Gross profit amounted to RMB2,119.5 million, a decrease
of 46.0% as compared with the same period last year. EBITDA was RMB920.8 million, representing a
year-on-year decrease of 66.5%. Profit attributable to owners of the Company was RMB347.6 million,
representing a year-on-year decrease of 81.6%. Earnings per share were RMB17.62 cents.
During the Period, segmental revenue (including inter-segment sales) of intermediate products, bulk
medicine and finished products was RMB1,976.5 million, RMB3,148.4 million and RMB2,866.6 million
respectively, representing a decrease of 14.2%, an increase of 5.0% and a decrease of 27.9% respectively as
compared with the same period in the previous year. Segmental profit of intermediate products, bulk
medicine and finished products amounted to RMB191.4 million, RMB79.7 million and RMB398.0 million
respectively, representing a decrease of 69.8%, 68.2% and 73.6% respectively as compared to last
corresponding period.
Optimising Financial Structure
In terms of finance, the Group continuously optimised its financial structure to improve liquidity by
adjusting the mix of onshore and offshore borrowings, balancing long-term and short-term borrowings to
reduce the finance expenses and enhance financial flexibility and efficiency in the utilisation of funds and
maintain robust financial position. The Group has used Renminbi as the main borrowing currency to reduce
the risk of exchange rate fluctuation and finance costs. The Group has also secured several long-term project
loans for financing of its capital expenditures. During the Period, the finance costs of the Group were
approximately RMB44.9 million, representing a year-on-year increase of 116.1% mainly due to the increase
in project financing borrowings.
As at 30 June 2026, the Group’s net bank balances and cash (after deducting borrowings and trade payables
under supplier finance arrangement) amounted to RMB3,416.0 million.
Liquidity and Financial Resources
As at 30 June 2026, the Group had pledged bank deposits, cash and bank balances amounted to
RMB11,729.7 million (31 December 2025: RMB11,234.9 million).
As at 30 June 2026, the Group had interest-bearing borrowings of approximately RMB5,924.4 million (31
December 2025: RMB4,979.3 million), all denominated in Renminbi and of which RMB1,180.8 million
with maturity within one year. Borrowings of approximately RMB779.2 million are fixed rates loans while
the remaining balance of approximately RMB5,145.2 million are at floating rates. The directors expect that
all such borrowings will either be repaid by internally generated funds or rolled over upon maturity and will
continue to provide funding to the Group’s operations.
As at 30 June 2026, current assets of the Group amounted to approximately RMB19,587.3 million (31
December 2025: RMB18,469.5 million). Net current assets increased from RMB8,390.4 million as at 31
December 2025 to RMB10,012.9 million as at 30 June 2026. The Group’s current ratio was approximately
2.05 as at 30 June 2026 as compared with 1.83 as at 31 December 2025. As at 30 June 2026, the Group had
total assets of approximately RMB32,112.7 million (31 December 2025: RMB30,900.5 million) and total
liabilities of approximately RMB14,817.4 million (31 December 2025: RMB13,425.2 million). At 30 June
2026, equity attributable to shareholders of the Company amounted to RMB17,216.5 million (31 December
2025: RMB17,393.0 million. As at 30 June 2026, the Group’s net cash and bank balances (after deducting
borrowings and trade payables under supplier finance arrangement) amounted to RMB3,416.0 million (31
December 2025: RMB4,027.1 million).
Contingent Liabilities
As at 30 June 2026 and 31 December 2025, the Group had no material contingent liabilities.
Currency Exchange Exposures
The Group’s purchases and sales are mainly denominated in Renminbi, United States dollars and Hong Kong
dollars. The operating expenses of the Group are mainly denominated in Renminbi and Hong Kong dollars.
The Group’s borrowings are denominated in Renminbi. The Group’s treasury policy is in place to monitor
and manage its exposure to fluctuation in exchange rates. Besides, the Group will conduct periodic review of
its exposure to foreign exchange risk and may use financial instrument for hedging purpose when considered
appropriate.
Employees and Remuneration Policies
As at 30 June 2026, the Group had approximately 18,000 (31 December 2025: 18,000) employees in Hong
Kong and Mainland China. The employees are remunerated with basic salary, bonus and other benefits in
kind with reference to industry practice and their individual performance.
The Company has adopted a share award scheme in October 2023 and granted a total of 12,096,900 award
shares to selected directors and employees, vesting in three years, to encourage and retain such individuals
for the continual operation and development of the Group. As at 30 June 2026, the scheme has completed
two vests of the awarded shares.
Environmental, Social and Governance
Upholding the corporate tenet of “Making Life More Valuable”, the Group integrates the concept of
sustainable development into its business operations and decision-making. The Group actively fulfills its
social responsibilities by continuously investing in various fields such as education, disaster relief, and
community care to contribute to the society. Simultaneously, we respond wholeheartedly the national policy
of green and sustainable development, promoting industrial upgrading and the green and low-carbon
transformation.
During the reporting period, the Group’s MSCI ESG rating has been upgraded to “AA”, and the Group also
received numerous honors such as the “Excellent ESG Award” at the 9th China Excellence IR Awards and
the “ESG Responsible Enterprise Award” at CPHI.
Use of Proceeds from Placing of Shares
On 25 July 2025, The Company completed the placing of an aggregate of 156,000,000 new shares to not less
than six placees at the placing price of HK$14.16 per share. The gross proceeds and the net proceeds (after
deduction of the relevant expenses and fees) from the Placing amounted to HK$2,209.0 million and
HK$2,168.2 million (equivalent to RMB1,989.9 million), respectively. The Company intends to allocate the
net proceeds from the placing as follows:
(a)
approximately 60%, or HK$1,300.9 million, will be used for capital expenditure related to the
construction and expansion of the Company’s manufacturing facilities, including the Inner Mongolia
plant and the Zhuhai plants, strengthen external collaboration, expand the Company’s international
business, as well as other general corporate purposes; and
(b)
approximately 40%, or HK$867.3 million, will be used for research and development of innovative
product candidates, including the clinical trial of UBT251, and other pipelines under development.
As at 30 June 2026, proceeds from the placing have been used as:
approximately RMB890.7 million for capital expenditure related to the construction and expansion of
the manufacturing facilities, strengthen external collaboration, expand the international business, as
well as other general corporate purposes; and
approximately RMB678.7 million for research and development of innovative product candidates and
other pipelines under development.
The remaining proceeds from the placing are expected to be fully utilised on or before 31 December 2028.
Such expected time frame is based on the Board’s best assessment, and is subject to adjustment depending on
the Company’s future development, market conditions and prevailing business circumstances.
Litigations
During the six months ended 30 June 2026, the Group has no material litigations.
FUTURE PROSPECTS
The year 2026 marks the beginning of China’s “15th Five-Year Plan”. As full-chain support policies for
innovative drugs are gradually implemented, the pace of innovation and upgrading in the pharmaceutical
industry will continue to accelerate, and systems related to review and approval, market access and payment
are expected to be further improved. Meanwhile, the internationalisation of domestically developed
innovative drugs is gaining momentum, and enterprises with global competitiveness will embrace new
growth opportunities in overseas markets.
With its solid industrial foundation and forward-looking layout, the Group is confident in seizing
opportunities and addressing challenges. Upholding the innovation-driven development strategy, the Group
will accelerate the R&D and clinical development of key innovative products, deepen vertical integration
along the industrial chain to fully leverage its integration advantages, and advance its internationalisation
strategy by improving its R&D, production and commercialisation systems to internationally competitive
standards and promoting global R&D cooperation and overseas market expansion. We will unwaveringly
pursue the path of high-quality and sustainable development, striving to create greater value for our
shareholders, patients and society.
PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES OF THE COMPANY
During the six months ended 30 June 2026, the Company has repurchased a total of 2,750,000 shares on the
Stock Exchange at total consideration (including transaction costs) of approximately HK$22,627,000.
Particulars of the repurchases are as follows:
Month
January to May
June
Purchase Price
Highest Lowest
HK$
HK$
No. of Shares
2,750,000
8.40
7.98
Total
Consideration
HK$
22,627,000
All the repurchased shares were subsequently cancelled in July 2026. Save for the above, neither the
Company, nor any of its subsidiaries purchased, sold or redeemed any of the listed securities of the Company
during the six months ended 30 June 2026.
CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS
The Company has adopted the Model Code as set out in Appendix 10 of the Rules Governing the Listing of
Securities (“Listing Rules”) on the Stock Exchange as its code of conduct for dealings in securities of the
Company by the Board. Following a specific enquiry, all directors confirmed that they have complied with the
required standards set out in the Model Code throughout the six months ended 30 June 2026.
CORPORATE GOVERNANCE
The Board is of the view that best corporate governance is crucial to safeguard the interests of shareholders
and to enhance the Group’s performance. The Board is dedicated to maintaining and ensuring a high
standard of corporate governance. For the six months ended 30 June 2026, the Company has applied and
complied with the applicable code provisions set out in the Corporate Governance Code (“CG Code”) and
Corporate Governance Report contained in Appendix C1 of Listing Rules, except for deviation which is
summarised below:
- Code Provision C.2.1
Under the code provision C.2.1 of the CG Code, the roles of chairman and chief executive officer should be
separated and should not be performed by the same individual. During the six months ended 30 June 2026,
the Company did not have a chief executive officer. The Company will make appointment to fill the post as
appropriate.
AUDIT COMMITTEE
The Audit Committee comprises of three independent non-executive directors, namely Mr. Chong Peng Oon,
Prof. Song Ming and Dr. Fu Qiushi. The Audit Committee has reviewed the unaudited condensed
consolidated financial statements for the six months ended 30 June 2026. The Audit Committee has relied on
a review conducted by the Company’s external auditor in accordance with Hong Kong Standard on Review
Engagements 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the
Entity” issued by the HKICPA and representations from the management.
APPRECIATION
On behalf of the Board, I would like to take this opportunity to express my gratitude to our shareholders
and partners for their full trust and support, as well as to our staff for their efforts and contributions. I hope
we can join hands and create a better future together.
On behalf of the Board
Tsoi Hoi Shan
Chairman
Hong Kong, 31 August 2026
As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms.
Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming
and Dr. Fu Qiushi as independent non-executive directors.